PETACH TIKVA, Israel, January 30 /PRNewswire-FirstCall/ -- Healthcare Technologies, Ltd. announced today that the previously disclosed agreement between Healthcare, ImmvaRx, Inc. and Gamida for Life BV, dated as of July 26, 2005, has been terminated in accordance with its terms.
About Healthcare Technologies
Healthcare Technologies through it subsidiaries and affiliate, Gamidor Diagnostics (1984) Ltd., Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.
ImmvaRx is an immunotherapeutics biotechnology company focusing on immune system based therapies. Specifically, the company develops therapeutic, diagnostic, and research products with an initial focus on the Adenocarcinoma family of cancers and Type 1 allergies. The immunotherapies include both humanized antibody and vaccine treatments.
SAFE HARBOR: This press release contains certain forward looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of Healthcare Technologies Ltd. Many factors could cause the actual results, performance or achievements of Healthcare or the above described transaction to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking.
FOR: Healthcare Technologies Ltd.
CONTACT: Eran Rotem, CFO, +972-3-9277232/3
Healthcare Technologies Ltd.
CONTACT: Contact: Healthcare Technologies Ltd., Eran Rotem, CFO,+972-3-9277232/3